reported that in PDAC patients, high MUC16 protein expression correlates with faster tumor progression, more metastasis, aggressive subtypes like basal-like and squamous tumors, and shorter survival, with its abnormally glycosylated form activating AKT and GSK3β signaling pathways, thereby exacerbating tumor malignancy (65). This evidence concerns the gene MUC16 and neoplasm.